Description of Research Expertise:
Dr Brose is the director of the Thyroid Cancer Therapuetics Program and is a global leader in the development of the new field of thyroid cancer oncology. Her Phase II clinical trial of sorafenib in patients with advanced thyroid cancer lead to the successful completion of the first Phase III study, in this disease group (RAI refractory thyroid cancer). She was also one of the top accuers and lead site for the Phase III trial of cabozantinib for advance medullary thyroid cancer, which lead to FDA approval of this agent in November of 2012. Requested to speak and teach worldwide on her experience in the the use of novel agents to treat patients with all types of advanced thyroid cancer (Differentiate, Medullary, and Anaplastic), she is a global leader and educator to physicians and patients alike.
Dr. Brose also runs a lab in the field of translational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. Most of her research centers on translational projects directly related to samples obtained in the course of her clinical trial program. However, occasionally, science leads to leads in other tumor types. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincal tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis, and whole and targeted genome sequencing. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.
Wei S, LiVolsi VA, Brose MS, Montone KT, Morrissette JJ, Baloch ZW.: STK11 Mutation Identified in Thyroid Carcinoma. Endocr Pathol 27 (1): 65-9,2016.
Brose, M.S., Cabanillas, M.E., Cohen, E.E., Wirth, L.J., Riehl,T., Yue, H., Sherman, S.I., Sherman, E.J.: An open-label, multicentre, phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAFV600 mutation and resistant to radioactive iodine Lancet Oncology : 2016.
Mark Yarchoan, M., Ma,C, Troxel, A.B., Stopenski, S.J., Tang, W.,
Cohen, A.B. Pappas-Paxinos, M., Johnson, B.A., Chen, E.Y.,
Feldman, M.D., Brose, M.S.: pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer Hormones and Cancer Hormones and Cancer : 2016.
Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando, Y, Hasegawa Y, Park do J, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G,Schlumberger M, Brose MS.: Safety and tolerability of sorafenib in patients with
radioiodine-refractory thyroid cancer Endocr Relat Cancer 22 (6): 877-87,2015.
Yarchoan M, LiVolsi VA, Brose MS.: Reply to C. Bal et al and M. Xing. J Clin Oncol. 2015 Aug 1;33(22):2483. 33 (22): 2483,2015.
Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.: Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 33 (7): 786-809,2015.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer N Engl J Med 372 (7): 621-630,2015.
Brose MS, Schlumberger M, Peña C, Kappeler C: Sorafenib for patients with differentiated thyroid cancer--authors' reply. Lancet 385 (9964): 228-229,2015.
Yarchoan M, LiVolsi VA, Brose MS: BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 33 (1): 7-8,2015.
Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.: A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24 (10): 1508-1514,2014.
View all publications